Repeated Intravenous Thrombolysis for Early Recurrent Stroke | Zendy

Timo Kahles | Zendy; MarieLuise Mono | Zendy; Mirjam R. Heldner | Zendy; Ralf W. Baumgartner | Zendy; Hakan Sarıkaya | Zendy; Andreas R. Luft | Zendy; Stephan Bohlhalter | Zendy; Christopher Traenka | Zendy; Stefan T. Engelter | Zendy; Natalia Kurka | Zendy; Martin Köhrmann | Zendy; Sami Curtze | Zendy; Patrik Michel | Zendy; Turgut Tatlisumak | Zendy; Krassen Nedeltchev | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Repeated Intravenous Thrombolysis for Early Recurrent Stroke

Author(s) -

Timo Kahles,

MarieLuise Mono,

Mirjam R. Heldner,

Ralf W. Baumgartner,

Hakan Sarıkaya,

Andreas R. Luft,

Stephan Bohlhalter,

Christopher Traenka,

Stefan T. Engelter,

Natalia Kurka,

Martin Köhrmann,

Sami Curtze,

Patrik Michel,

Turgut Tatlisumak,

Krassen Nedeltchev

Publication year - 2016

Publication title -

stroke

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 3.397

H-Index - 319

eISSN - 1524-4628

pISSN - 0039-2499

DOI - 10.1161/strokeaha.116.013599

Subject(s) - medicine , interquartile range , thrombolysis , modified rankin scale , stroke (engine) , fibrinolytic agent , tissue plasminogen activator , surgery , anesthesia , ischemic stroke , ischemia , myocardial infarction , mechanical engineering , engineering

Intravenous thrombolysis (IVT) within 4.5 hours from symptom onset improves functional outcome in patients with acute ischemic stroke. Its use in patients with previous stroke within the preceding 3 months is contraindicated because of the assumed higher risk of intracranial hemorrhage. In addition, tissue-type plasminogen activator may itself promote neurotoxicity and blood-brain barrier disruption. However, safety and effectiveness of repeated IVT is essentially unknown in patients with early (<3 months) recurrent stroke (ERS), because they were excluded from thrombolysis trials. This article reports the largest case series of repeated IVT in ERS.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research